274 related articles for article (PubMed ID: 20658156)
21. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
22. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
23. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?
Cengiz C; Ardicoglu Y; Bulut S; Boyacioglu S
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):813-9. PubMed ID: 19820404
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Van Rooyen DM; Gan LT; Yeh MM; Haigh WG; Larter CZ; Ioannou G; Teoh NC; Farrell GC
J Hepatol; 2013 Jul; 59(1):144-52. PubMed ID: 23500152
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Ansquer JC; Bekaert I; Guy M; Hanefeld M; Simon A;
Am J Cardiovasc Drugs; 2009; 9(2):91-101. PubMed ID: 19331437
[TBL] [Abstract][Full Text] [Related]
26. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.
Lee HY; Jun DW; Kim HJ; Oh H; Saeed WK; Ahn H; Cheung RC; Nguyen MH
Korean J Intern Med; 2019 Mar; 34(2):296-304. PubMed ID: 29551054
[TBL] [Abstract][Full Text] [Related]
27. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
Charlton M; Angulo P; Chalasani N; Merriman R; Viker K; Charatcharoenwitthaya P; Sanderson S; Gawrieh S; Krishnan A; Lindor K
Hepatology; 2008 Feb; 47(2):484-92. PubMed ID: 18220286
[TBL] [Abstract][Full Text] [Related]
28. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease.
Nobili V; Manco M; Ciampalini P; Diciommo V; Devito R; Piemonte F; Comparcola D; Guidi R; Marcellini M
Eur J Endocrinol; 2006 Nov; 155(5):735-43. PubMed ID: 17062890
[TBL] [Abstract][Full Text] [Related]
29. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
[TBL] [Abstract][Full Text] [Related]
30. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
31. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.
Alkhouri N; Tamimi TA; Yerian L; Lopez R; Zein NN; Feldstein AE
Dig Dis Sci; 2010 Sep; 55(9):2644-50. PubMed ID: 19960252
[TBL] [Abstract][Full Text] [Related]
32. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303
[TBL] [Abstract][Full Text] [Related]
34. [An inhibitor of intestinal cholesterol transporter].
Sano M
Nihon Rinsho; 2013 Sep; 71(9):1661-6. PubMed ID: 24205731
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?
Husain NE; Hassan AT; Elmadhoun WM; Ahmed MH
Expert Opin Drug Saf; 2015; 14(9):1445-55. PubMed ID: 26134926
[TBL] [Abstract][Full Text] [Related]
37. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update.
Musso G; Cassader M; Gambino R
Curr Opin Lipidol; 2011 Dec; 22(6):489-96. PubMed ID: 21986643
[TBL] [Abstract][Full Text] [Related]
38. Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.
Ahmed MH
World J Gastroenterol; 2010 Apr; 16(13):1555-7. PubMed ID: 20355232
[TBL] [Abstract][Full Text] [Related]
39. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.
Lebensztejn DM; Wojtkowska M; Skiba E; Werpachowska I; Tobolczyk J; Kaczmarski M
Adv Med Sci; 2009; 54(2):177-82. PubMed ID: 20022856
[TBL] [Abstract][Full Text] [Related]
40. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
Mikhailidis DP; Sibbring GC; Ballantyne CM; Davies GM; Catapano AL
Curr Med Res Opin; 2007 Aug; 23(8):2009-26. PubMed ID: 17659159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
